← Evidence map

ArticleMicrobial cell factories2024

Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19.

Norma A Valdez-Cruz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19. | Socratic